Antibody data
- Antibody Data
- Antigen structure
- References [64]
- Comments [0]
- Validations
- Western blot [2]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA5-14104 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Estrogen Receptor alpha Antibody Cocktail
- Antibody type
- Monoclonal
- Antigen
- Recombinant full-length protein
- Description
- MA5-14104 is a mixture of two monoclonal antibodies that target Estrogen Receptor alpha. Staining of formalin-fixed, paraffin-embedded tissues requires boiling tissues in 10mM citrate buffer (pH 6.0) for 10-20 min, followed by cooling at room temperature for 20 min. A recommended positive control is MCF-7 cells.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 1D5, 6F11
- Vial size
- 500 µL
- Concentration
- Conc. Not Determined
- Storage
- 4° C
Submitted references Ribociclib Induces Broad Chemotherapy Resistance and EGFR Dependency in ESR1 Wildtype and Mutant Breast Cancer.
Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition.
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.
Unraveling the regulatory connections between two controllers of breast cancer cell fate.
Progesterone and estrogen receptors in conjunctival melanoma and nevi.
Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior.
Breast cancer tissue slices as a model for evaluation of response to rapamycin.
Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast.
Immunohistochemical study of pElk-1 expression in human breast cancer: association with breast cancer biologic profile and clinicopathologic features.
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature.
Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.
Validation of the aging hen (Gallus gallus domesticus) as an animal model for uterine leiomyomas.
Localization and hormonal regulation of endometrial matrix metalloproteinase-26 in the rhesus macaque.
Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours.
Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma.
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients.
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern.
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
The effect of maturation and age on oestrogen-induced functional hypertrophy of the female rabbit bladder.
Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Hormone receptor expressions and proliferation markers in postmenopausal endometrial polyps.
Estrogen induced functional hypertrophy and increased force generation of the female rabbit bladder.
Spontaneously occurring fibroid tumors of the laying hen oviduct.
Spontaneously occurring fibroid tumors of the laying hen oviduct.
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
PAK1 hyperactivation is sufficient for mammary gland tumor formation.
Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.
Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert.
Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism.
The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform.
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Characterization of reproductive steroid receptors and response to estrogen in a rat serotonergic cell line.
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Cellular and molecular targets of estrogen in normal human breast tissue.
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
Mayayo-Peralta I, Faggion B, Hoekman L, Morris B, Lieftink C, Goldsbrough I, Buluwela L, Siefert JC, Post H, Altelaar M, Beijersbergen R, Ali S, Zwart W, Prekovic S
Cancers 2021 Dec 16;13(24)
Cancers 2021 Dec 16;13(24)
Mathematical modelling of breast cancer cells in response to endocrine therapy and Cdk4/6 inhibition.
He W, Demas DM, Conde IP, Shajahan-Haq AN, Baumann WT
Journal of the Royal Society, Interface 2020 Aug;17(169):20200339
Journal of the Royal Society, Interface 2020 Aug;17(169):20200339
Tissue biomarkers in prognostication of serous ovarian cancer following neoadjuvant chemotherapy.
Khandakar B, Mathur SR, Kumar L, Kumar S, Datta Gupta S, Iyer VK, Kalaivani M
BioMed research international 2014;2014:401245
BioMed research international 2014;2014:401245
Unraveling the regulatory connections between two controllers of breast cancer cell fate.
Lee J, Tiwari A, Shum V, Mills GB, Mancini MA, Igoshin OA, Balázsi G
Nucleic acids research 2014 Jun;42(11):6839-49
Nucleic acids research 2014 Jun;42(11):6839-49
Progesterone and estrogen receptors in conjunctival melanoma and nevi.
Bredow L, Stützel L, Böhringer D, Gundlach E, Reinhard T, Auw-Haedrich C
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2014 Feb;252(2):359-65
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2014 Feb;252(2):359-65
Characterization of estrogen response element binding proteins as biomarkers of breast cancer behavior.
Kruer TL, Cummins TD, Powell DW, Wittliff JL
Clinical biochemistry 2013 Nov;46(16-17):1739-46
Clinical biochemistry 2013 Nov;46(16-17):1739-46
Breast cancer tissue slices as a model for evaluation of response to rapamycin.
Grosso SH, Katayama ML, Roela RA, Nonogaki S, Soares FA, Brentani H, Lima L, Folgueira MA, Waitzberg AF, Pasini FS, Góes JC, Brentani MM
Cell and tissue research 2013 Jun;352(3):671-84
Cell and tissue research 2013 Jun;352(3):671-84
Comparison of the PharmDx immunohistochemical system with standard methods for assessing estrogen and progesterone receptors in invasive carcinoma of the breast.
Gill MS, Paish EC, Ronan J, Green AR, Ellis IO, Lee AH
Applied immunohistochemistry & molecular morphology : AIMM 2013 Jan;21(1):90-3
Applied immunohistochemistry & molecular morphology : AIMM 2013 Jan;21(1):90-3
Immunohistochemical study of pElk-1 expression in human breast cancer: association with breast cancer biologic profile and clinicopathologic features.
Laliotis A, Vrekoussis T, Kafousi M, Sanidas E, Askoxilakis J, Melissas J, Mavroudis D, Castanas E, Stathopoulos EN
Breast (Edinburgh, Scotland) 2013 Feb;22(1):89-95
Breast (Edinburgh, Scotland) 2013 Feb;22(1):89-95
Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO
Molecular cancer 2013 Feb 4;12:9
Molecular cancer 2013 Feb 4;12:9
Malignant transformation of adenomyoepithelioma of the breast by a monophasic population: a report of two cases and review of literature.
Marian C, Boila A, Soanca D, Malau M, Podeanu DM, Resetkova E, Stolnicu S
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2013 Apr;121(4):272-9
APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2013 Apr;121(4):272-9
Lowering oral contraceptive norethindrone dose increases estrogen and progesterone receptor levels with no reduction in proliferation of breast epithelium: a randomized trial.
Hovanessian-Larsen L, Taylor D, Hawes D, Spicer DV, Press MF, Wu AH, Pike MC, Pearce CL
Contraception 2012 Sep;86(3):238-43
Contraception 2012 Sep;86(3):238-43
Validation of the aging hen (Gallus gallus domesticus) as an animal model for uterine leiomyomas.
Machado SA, Bahr JM, Hales DB, Braundmeier AG, Quade BJ, Nowak RA
Biology of reproduction 2012 Oct;87(4):86
Biology of reproduction 2012 Oct;87(4):86
Localization and hormonal regulation of endometrial matrix metalloproteinase-26 in the rhesus macaque.
Almeida-Francia CC, Keator CS, Mah K, Holden L, Hergert C, Slayden OD
Human reproduction (Oxford, England) 2012 Jun;27(6):1723-34
Human reproduction (Oxford, England) 2012 Jun;27(6):1723-34
Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation.
Chung K, Hovanessian-Larsen LJ, Hawes D, Taylor D, Downey S, Spicer DV, Stanczyk FZ, Patel S, Anderson AR, Pike MC, Wu AH, Pearce CL
Breast cancer research and treatment 2012 Apr;132(2):653-60
Breast cancer research and treatment 2012 Apr;132(2):653-60
Prediction of BRCA2-association in hereditary breast carcinomas using array-CGH.
Joosse SA, Brandwijk KI, Devilee P, Wesseling J, Hogervorst FB, Verhoef S, Nederlof PM
Breast cancer research and treatment 2012 Apr;132(2):379-89
Breast cancer research and treatment 2012 Apr;132(2):379-89
Specific detection of OCT3/4 isoform A/B/B1 expression in solid (germ cell) tumours and cell lines: confirmation of OCT3/4 specificity for germ cell tumours.
Rijlaarsdam MA, van Herk HA, Gillis AJ, Stoop H, Jenster G, Martens J, van Leenders GJ, Dinjens W, Hoogland AM, Timmermans M, Looijenga LH
British journal of cancer 2011 Sep 6;105(6):854-63
British journal of cancer 2011 Sep 6;105(6):854-63
Role of Fos-related antigen 1 in the progression and prognosis of ductal breast carcinoma.
Logullo AF, Stiepcich MM, Osório CA, Nonogaki S, Pasini FS, Rocha RM, Soares FA, Brentani MM
Histopathology 2011 Mar;58(4):617-25
Histopathology 2011 Mar;58(4):617-25
Differential expression pattern of estrogen receptors, aromatase, and sulfotransferase in breast cancer tissue and corresponding lymph node metastases.
Gschwantler-Kaulich D, Fink-Retter A, Czerwenka K, Hudelist G, Kaulich A, Kubista E, Singer CF
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011 Jun;32(3):501-8
Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011 Jun;32(3):501-8
Genomic signature of BRCA1 deficiency in sporadic basal-like breast tumors.
Joosse SA, Brandwijk KI, Mulder L, Wesseling J, Hannemann J, Nederlof PM
Genes, chromosomes & cancer 2011 Feb;50(2):71-81
Genes, chromosomes & cancer 2011 Feb;50(2):71-81
The impact of inter-observer variation in pathological assessment of node-negative breast cancer on clinical risk assessment and patient selection for adjuvant systemic treatment.
Bueno-de-Mesquita JM, Nuyten DS, Wesseling J, van Tinteren H, Linn SC, van de Vijver MJ
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Jan;21(1):40-7
Annals of oncology : official journal of the European Society for Medical Oncology 2010 Jan;21(1):40-7
Integration of DNA copy number alterations and prognostic gene expression signatures in breast cancer patients.
Horlings HM, Lai C, Nuyten DS, Halfwerk H, Kristel P, van Beers E, Joosse SA, Klijn C, Nederlof PM, Reinders MJ, Wessels LF, van de Vijver MJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jan 15;16(2):651-63
Clinical cancer research : an official journal of the American Association for Cancer Research 2010 Jan 15;16(2):651-63
Cross-species comparison of aCGH data from mouse and human BRCA1- and BRCA2-mutated breast cancers.
Holstege H, van Beers E, Velds A, Liu X, Joosse SA, Klarenbeek S, Schut E, Kerkhoven R, Klijn CN, Wessels LF, Nederlof PM, Jonkers J
BMC cancer 2010 Aug 24;10:455
BMC cancer 2010 Aug 24;10:455
HER-2/neu (c-erbB-2) oncoprotein in hyperplastic endometrial polyps detected in two cats.
Misirlioglu D, Nak D, Ozyigit MO, Nak Y, Akkoc A
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Journal of feline medicine and surgery 2009 Oct;11(10):885-8
Prediction of BRCA1-association in hereditary non-BRCA1/2 breast carcinomas with array-CGH.
Joosse SA, van Beers EH, Tielen IH, Horlings H, Peterse JL, Hoogerbrugge N, Ligtenberg MJ, Wessels LF, Axwijk P, Verhoef S, Hogervorst FB, Nederlof PM
Breast cancer research and treatment 2009 Aug;116(3):479-89
Breast cancer research and treatment 2009 Aug;116(3):479-89
Transitional cell tumors of the ovary: a compact group with a heterogeneous histological and immunophenotypical pattern.
Ceauşu M, Terzea D, Georgescu A, Dobrea C, Mihai M, Iosif C, Vasilescu F, Ardeleanu C
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2008;49(4):513-6
Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2008;49(4):513-6
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer.
Pietersen AM, Horlings HM, Hauptmann M, Langerød A, Ajouaou A, Cornelissen-Steijger P, Wessels LF, Jonkers J, van de Vijver MJ, van Lohuizen M
Breast cancer research : BCR 2008;10(6):R109
Breast cancer research : BCR 2008;10(6):R109
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L
Anti-cancer drugs 2008 Mar;19(3):317-23
Anti-cancer drugs 2008 Mar;19(3):317-23
Predictive value of serum anti-p53 antibodies, carcino-embryonic antigen, carbohydrate antigen 15-3, estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 in taxane-based and anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer patients.
Bao H, Yu D, Wang J, Qiu T, Yang J, Wang L
Anti-cancer drugs 2008 Mar;19(3):317-23
Anti-cancer drugs 2008 Mar;19(3):317-23
Estrogen receptor beta (ERbeta) in endometrial simple hyperplasia and endometrioid carcinoma.
Chakravarty D, Srinivasan R, Ghosh S, Rajwanshi A, Gopalan S
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):535-42
Applied immunohistochemistry & molecular morphology : AIMM 2008 Dec;16(6):535-42
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.
Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R
Cancer cell 2007 Oct;12(4):395-402
Cancer cell 2007 Oct;12(4):395-402
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas.
Barbareschi M, Buttitta F, Felicioni L, Cotrupi S, Barassi F, Del Grammastro M, Ferro A, Dalla Palma P, Galligioni E, Marchetti A
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 15;13(20):6064-9
Clinical cancer research : an official journal of the American Association for Cancer Research 2007 Oct 15;13(20):6064-9
The effect of maturation and age on oestrogen-induced functional hypertrophy of the female rabbit bladder.
Onal B, Levin RM, Kogan BA, Whitbeck C, Chichester P, Walebowa O, Mannikarottu AS
BJU international 2007 Mar;99(3):674-9
BJU international 2007 Mar;99(3):674-9
Altered expression of estrogen receptor alpha and beta in advanced gastric adenocarcinoma: correlation with prothymosin alpha and clinicopathological parameters.
Wang M, Pan JY, Song GR, Chen HB, An LJ, Qu SX
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007 Mar;33(2):195-201
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2007 Mar;33(2):195-201
Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
Schmidt MK, Tollenaar RA, de Kemp SR, Broeks A, Cornelisse CJ, Smit VT, Peterse JL, van Leeuwen FE, Van't Veer LJ
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007 Jan 1;25(1):64-9
Hormone receptor expressions and proliferation markers in postmenopausal endometrial polyps.
Inceboz US, Nese N, Uyar Y, Ozcakir HT, Kurtul O, Baytur YB, Kandiloglu AR, Caglar H, Fraser IS
Gynecologic and obstetric investigation 2006;61(1):24-8
Gynecologic and obstetric investigation 2006;61(1):24-8
Estrogen induced functional hypertrophy and increased force generation of the female rabbit bladder.
Lin AD, Levin R, Kogan B, Whitbeck C, Chichester P, Sokol R, Mannikarottu A
Neurourology and urodynamics 2006;25(5):473-9
Neurourology and urodynamics 2006;25(5):473-9
Spontaneously occurring fibroid tumors of the laying hen oviduct.
Berry W, Doernte A, Conner M, Barnes M, Oates S
Poultry science 2006 Nov;85(11):1969-74
Poultry science 2006 Nov;85(11):1969-74
Spontaneously occurring fibroid tumors of the laying hen oviduct.
Berry W, Doernte A, Conner M, Barnes M, Oates S
Poultry science 2006 Nov;85(11):1969-74
Poultry science 2006 Nov;85(11):1969-74
Molecular subtypes of breast cancer and amplification of topoisomerase II alpha: predictive role in dose intensive adjuvant chemotherapy.
Hannemann J, Kristel P, van Tinteren H, Bontenbal M, van Hoesel QG, Smit WM, Nooij MA, Voest EE, van der Wall E, Hupperets P, de Vries EG, Rodenhuis S, van de Vijver MJ
British journal of cancer 2006 Nov 20;95(10):1334-41
British journal of cancer 2006 Nov 20;95(10):1334-41
PAK1 hyperactivation is sufficient for mammary gland tumor formation.
Wang RA, Zhang H, Balasenthil S, Medina D, Kumar R
Oncogene 2006 May 11;25(20):2931-6
Oncogene 2006 May 11;25(20):2931-6
Overexpression of cyclins D1 and D3 during estrogen-induced breast oncogenesis in female ACI rats.
Weroha SJ, Li SA, Tawfik O, Li JJ
Carcinogenesis 2006 Mar;27(3):491-8
Carcinogenesis 2006 Mar;27(3):491-8
Antagonist-induced, activation function-2-independent estrogen receptor alpha phosphorylation.
Lipfert L, Fisher JE, Wei N, Scafonas A, Su Q, Yudkovitz J, Chen F, Warrier S, Birzin ET, Kim S, Chen HY, Tan Q, Schmidt A, Dininno F, Rohrer SP, Hammond ML, Rodan GA, Freedman LP, Reszka AA
Molecular endocrinology (Baltimore, Md.) 2006 Mar;20(3):516-33
Molecular endocrinology (Baltimore, Md.) 2006 Mar;20(3):516-33
Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran desert.
Turbyville TJ, Wijeratne EM, Liu MX, Burns AM, Seliga CJ, Luevano LA, David CL, Faeth SH, Whitesell L, Gunatilaka AA
Journal of natural products 2006 Feb;69(2):178-84
Journal of natural products 2006 Feb;69(2):178-84
Selective spatial upregulation of intratumoral stromal aromatase in breast cancer patients: evidence for imbalance of local estrogen metabolism.
Singer CF, Fink-Retter A, Gschwantler-Kaulich D, Thalhammer T, Hudelist G, Mueller R, Czerwenka K, Kubista E
Endocrine-related cancer 2006 Dec;13(4):1101-7
Endocrine-related cancer 2006 Dec;13(4):1101-7
The presence of serum anti-p53 antibodies from patients with invasive ductal carcinoma of breast: correlation to other clinical and biological parameters.
Gao RJ, Bao HZ, Yang Q, Cong Q, Song JN, Wang L
Breast cancer research and treatment 2005 Sep;93(2):111-5
Breast cancer research and treatment 2005 Sep;93(2):111-5
The expression of Ki-67, p53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas. A clinicopathologic study.
Akhan SE, Yavuz E, Tecer A, Iyibozkurt CA, Topuz S, Tuzlali S, Bengisu E, Berkman S
Gynecologic oncology 2005 Oct;99(1):36-42
Gynecologic oncology 2005 Oct;99(1):36-42
Steroid hormone receptor expression and proliferation in rat mammary gland carcinomas induced by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Qiu C, Shan L, Yu M, Snyderwine EG
Carcinogenesis 2005 Apr;26(4):763-9
Carcinogenesis 2005 Apr;26(4):763-9
Molecular mechanism of estrogen receptor (ER)alpha-specific, estradiol-dependent expression of the progesterone receptor (PR) B-isoform.
Flötotto T, Niederacher D, Hohmann D, Heimerzheim T, Dall P, Djahansouzi S, Bender HG, Hanstein B
The Journal of steroid biochemistry and molecular biology 2004 Feb;88(2):131-42
The Journal of steroid biochemistry and molecular biology 2004 Feb;88(2):131-42
The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma.
Guler G, Uner A, Guler N, Han SY, Iliopoulos D, Hauck WW, McCue P, Huebner K
Cancer 2004 Apr 15;100(8):1605-14
Cancer 2004 Apr 15;100(8):1605-14
Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors.
Beliakoff J, Bagatell R, Paine-Murrieta G, Taylor CW, Lykkesfeldt AE, Whitesell L
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4961-71
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Oct 15;9(13):4961-71
Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF
Breast cancer research and treatment 2003 Mar;78(2):193-204
Breast cancer research and treatment 2003 Mar;78(2):193-204
Expression of sex steroid receptors and their co-factors in normal and malignant breast tissue: AIB1 is a carcinoma-specific co-activator.
Hudelist G, Czerwenka K, Kubista E, Marton E, Pischinger K, Singer CF
Breast cancer research and treatment 2003 Mar;78(2):193-204
Breast cancer research and treatment 2003 Mar;78(2):193-204
Characterization of reproductive steroid receptors and response to estrogen in a rat serotonergic cell line.
Bethea CL, Lu NZ, Reddy A, Shlaes T, Streicher JM, Whittemore SR
Journal of neuroscience methods 2003 Jul 15;127(1):31-41
Journal of neuroscience methods 2003 Jul 15;127(1):31-41
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Zinser GM, McEleney K, Welsh J
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Characterization of mammary tumor cell lines from wild type and vitamin D3 receptor knockout mice.
Zinser GM, McEleney K, Welsh J
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Molecular and cellular endocrinology 2003 Feb 28;200(1-2):67-80
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards RJ, Boobis AR, Iscan M
Cancer letters 2003 Dec 8;202(1):17-23
Cancer letters 2003 Dec 8;202(1):17-23
Expression of CYP3A4 in human breast tumour and non-tumour tissues.
Kapucuoglu N, Coban T, Raunio H, Pelkonen O, Edwards RJ, Boobis AR, Iscan M
Cancer letters 2003 Dec 8;202(1):17-23
Cancer letters 2003 Dec 8;202(1):17-23
Cellular and molecular targets of estrogen in normal human breast tissue.
Seth P, Porter D, Lahti-Domenici J, Geng Y, Richardson A, Polyak K
Cancer research 2002 Aug 15;62(16):4540-4
Cancer research 2002 Aug 15;62(16):4540-4
5alpha-reductases in human breast carcinoma: possible modulator of in situ androgenic actions.
Suzuki T, Darnel AD, Akahira JI, Ariga N, Ogawa S, Kaneko C, Takeyama J, Moriya T, Sasano H
The Journal of clinical endocrinology and metabolism 2001 May;86(5):2250-7
The Journal of clinical endocrinology and metabolism 2001 May;86(5):2250-7
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I
Breast cancer research and treatment 2001 Mar;66(2):135-42
Breast cancer research and treatment 2001 Mar;66(2):135-42
Biophenotypes and survival of BRCA1 and TP53 deleted breast cancer in young women.
Querzoli P, Albonico G, di Iasio MG, Ferretti S, Rinaldi R, Cariello A, Pedriali M, Matteuzzi M, Maestri I, Nenci I
Breast cancer research and treatment 2001 Mar;66(2):135-42
Breast cancer research and treatment 2001 Mar;66(2):135-42
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
El Khissiin A, Journé F, Laïos I, Seo HS, Leclercq G
Steroids 2000 Dec;65(12):903-13
Steroids 2000 Dec;65(12):903-13
Evidence of an estrogen receptor form devoid of estrogen binding ability in MCF-7 cells.
El Khissiin A, Journé F, Laïos I, Seo HS, Leclercq G
Steroids 2000 Dec;65(12):903-13
Steroids 2000 Dec;65(12):903-13
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Estrogen Receptor alpha (ER alpha) was performed by loading the indicated amounts of recombinant full-length human ER alpha (Product # A15674) and ER beta (Product # A15664) proteins, and 10 µL of PageRuler Prestained Protein Ladder (Product # 26616) per well onto a Novex® 4-20% Tris-Glycine polyacrylamide gel. Proteins were transferred to a PVDF membrane (Product # 88518) using the G2 Blotter (Product # 62288), and blocked with 5% milk in TBST for at least 1 hour at room temperature. ER alpha was detected at ~66 kD (left panel) using an ER alpha monoclonal antibody (Product # MA5-14104) at a dilution of 1:500 in blocking buffer overnight at 4C on a rocking platform, followed by an HRP-conjugated goat anti-mouse IgG secondary antibody (Product # 31430) at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Pico (Product # 34080). Directly alongside the above blot, a second blot containing the same recombinant ER alpha and ER beta protein samples was probed with an ER-beta specific polyclonal antibody (Product # PA1-313, right panel) at a dilution of 1:2000 overnight at 4C, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody (Product # 31460) at a dilution of 1:40,000. Chemiluminescent detection was again performed using SuperSignal West Pico (Product # 34080).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Estrogen Receptor alpha (ER) was performed by loading 20 µg of whole cell lysates (WCL) or nuclear extracts (NE) from the indicated breast cancer cell lines, and 10 µL of PageRuler Prestained Protein Ladder (Product # 26616) per well onto a Novex® 4-20% Tris-Glycine polyacrylamide gel. Proteins were transferred to a PVDF membrane (Product # 88518) using the G2 Blotter (Product # 62288), and blocked with 5% milk in TBST for at least 1 hour at room temperature. ER alpha was detected at ~66 kD (top panel) using an ER alpha monoclonal antibody (Product # MA5-14104) at a dilution of 1:500 in blocking buffer overnight at 4C on a rocking platform, followed by an HRP-conjugated goat anti-mouse IgG secondary antibody (Product # 31430) at a dilution of 1:40,000. Chemiluminescent detection was performed using SuperSignal West Dura (Product # 34075). To check for equivalent protein loading in each lane, a duplicate blot was probed with an HDAC1 polyclonal antibody (Product # PA1-860, bottom panel) at a dilution of 1:1000 overnight at 4C, followed by an HRP-conjugated goat anti-rabbit IgG secondary antibody (Product # 31460) at a dilution of 1:40,000. Chemiluminescent detection was also performed using SuperSignal West Dura (Product # 34075).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Estrogen Receptor alpha (ER alpha, green) in T47D and Hs 578T breast cancer cells. The cells were fixed and permeabilized with ice-cold methanol for 10 minutes at room temperature, and blocked with 0.3% BSA in PBS for at least 30 minutes at room temperature. Cells were stained with an ER alpha monoclonal antibody (Product # MA5-14104) at a dilution of 1:100 in blocking buffer overnight at 4C, and then incubated with a DyLight 488-conjugated goat anti-mouse IgG secondary antibody (Product # 35502) at a dilution of 1:500 for at least 1 hour at room temperature. Nuclei (blue) were stained with DAPI (Product # 62247). Images were taken on a Thermo Scientific ToxInsight Instrument at 20X magnification.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Formalin-fixed, paraffin-embedded human breast carcinoma stained with Estrogen Receptor antibody4 using peroxidase-conjugate and DAB chromogen. Note nuclear staining of tumor cells.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 ERalpha mutant cells are sensitive to various inhibitors of the cell cycle. ( A ) ERalpha-MutA and ERalpha-WT cells were cultured with ER degrader fulvestrant. After six days, cell viability was measured using CellTiter-Glo. Full circles depicted independent replicate ( n = 3) values, while the lines represent the curve fitting for sigmoidal (4PL) model (black, ERalpha-WT; red, ERalpha-MutA). ( B ) ERalpha-MutA and ERalpha-WT cells were cultured with ERalpha degrader AZD-9496. After six days, cell viability was measured using CellTiter-Glo. Full circles depicted independent replicate ( n = 3) values, while the lines represent the curve fitting for sigmoidal (4PL) model (black, ERalpha-WT; red, ERalpha-MutA). ( C ) Representative western blot showing expression of ERalpha in ERalpha-MutA and ERalpha-WT cell lines treated with 20 nM and 100 nM fulvestrant or AZD-9496 for 24 and 48 h, respectively. Hsp90 was used as loading control ( n = 3). ( D ) Schematic representation of the drug screen: ERalpha-MutA cells were seeded and cultured in full medium. On the following day, the drugs from the library were added at the concentration of 1 muM. After six-day treatment, CellTiter Blue assay was performed and viability measured using fluorescence reader. ( E ) Ranked plot showing viability of ERalpha-MutA cells following a six-day with 1 muM of the library compounds. Drugs that reduce the viability below 0.7 are considered effective. Black dots and red shade around these repre